About Scientific Commercialization
Scientific Commercialization is a Healthcare company based in Madison (United States) founded in 2005, and was acquired by The CM Group in February 2021. Pharmaceutical consulting and business intelligence services are provided. Its chief executive, as recorded, is Daniel Leonard. Its focus areas include Biopharma Outsourcing, Consulting and Diversified. Its competitors include Indegene, IntegriChain and ClearView Healthcare Partners; 2 of its 3 listed competitors have raised funding.
Company details
Scientific Commercialization was founded in 2005 and is based in Madison, United States. Operations focus on the pharmaceutical sector, where consulting services and business intelligence are delivered to support commercialization efforts. Expertise is applied in areas such as market analysis and strategic advisory, serving clients in the life sciences industry. The company is led by CEO Daniel Leonard, with activities centered on data-driven insights for pharmaceutical development.
- Headquarters Madison, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website scientificcommercialization.com
- Social LinkedIn Facebook
- Acquired by The CM Group (Feb 2021)
- Investors
- Acquired byThe CM Group
(Feb 2021)
Investors in Scientific Commercialization
Scientific Commercialization has secured backing from 1 investor. Prominent investors backing the company include The CM Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Medical meeting and marketing services for pharmaceuticals are provided. | 2005 | thecmgroup.com | Hingham, United States |
Investor details for Scientific Commercialization
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Scientific Commercialization
1 people are tracked at Scientific Commercialization (1 in leadership).
| Name | Role | Group |
|---|---|---|
Daniel Leonard | CEO | Leadership |
Complete people profiles for Scientific Commercialization
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Scientific Commercialization
2 dated milestones of Scientific Commercialization across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Scientific Commercialization is founded.
- Exit Acquired by The CM Group.
Competitors of Scientific Commercialization
Scientific Commercialization has 3 listed competitors in our database, 2 of them funded. They include Indegene, IntegriChain and ClearView Healthcare Partners.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indegene.com | 1998 | Princeton, United States | $220M | 350 | Suite solutions are provided for payers and healthcare providers. | |
| integrichain.com | 2005 | Philadelphia, United States | $2M | 320 | Inventory, order and customer relationship management solution for life science suppliers. | |
| clearviewhcp.com | 2008 | Newton, United States | 381 | Strategic consulting services are provided to life sciences companies. |
Detailed competitors of Scientific Commercialization
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Scientific Commercialization (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Scientific Commercialization
Complete news archive for Scientific Commercialization
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scientific Commercialization
Scientific Commercialization was founded in 2005.
Scientific Commercialization is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.
Daniel Leonard is the CEO of Scientific Commercialization, as recorded in our data.
Scientific Commercialization was founded in 2005 and is based in Madison, United States. Operations focus on the pharmaceutical sector, where consulting services and business intelligence are delivered to support commercialization efforts. Expertise is applied in areas such as market analysis and strategic advisory, serving clients in the life sciences industry. The company is led by CEO Daniel Leonard, with activities centered on data-driven insights for pharmaceutical development.
Scientific Commercialization's top competitors include Indegene, IntegriChain and ClearView Healthcare Partners.
Scientific Commercialization has 1 investor. Key investors include The CM Group.
Yes. Scientific Commercialization was acquired by The CM Group in February 2021.